Aurobindo Fights To Lift Ban On Biopsy Dye In Mylan Row
Aurobindo Pharma USA Inc. asked a Federal Circuit panel Monday to lift a court order temporarily blocking its new cancer biopsy product over infringement claims from competitor Mylan Inc., arguing the...To view the full article, register now.
Already a subscriber? Click here to view full article